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Open access under the ElseviNucleoside reverse-transcriptase inhibitor (NRTI) drugs are a major component of highly-active antiret-
roviral therapy (HAART). NRTI combinations have been demonstrated as producing a sustained reduction
in plasma viremia with an increased CD4 count, thereby showing clear clinical beneﬁts. Therefore, the
secondary effects caused by the combination of two NRTIs, mainly those related to ampliﬁcation of geno-
toxic effects, due to increased risk of DNA damage caused by these drugs, should be carefully examined.
We employed the standard version of the wing SMART in Drosophila melanogaster to obtain more detailed
knowledge about the genotoxic proﬁle of NRTI combinations of AZT + ddI, AZT + 3TC and AZT + d4T. Our
results showed that all combinations increased the frequencies of induction of mutant spots. The combi-
nations AZT + ddI and AZT + 3TC were shown to induce recombination rates ranging from 86.38% to
98.36% while AZT + d4T showed a large discrepancy between recombination and mutation percentages.
The combination index demonstrated that 3TC and d4T produced antagonism while ddI showed syner-
gistic effects in combination with AZT.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Nucleoside reverse transcriptase inhibitor (NRTI) drugs are a
major constituent of highly active antiretroviral therapy (HAART).
HAART drug combinations usually include NRTI drugs such as
zidovudine (30-azido-30-deoxythymidine, AZT, ZDV), lamivudine
([]-b-L-20-deoxy-30-thiacytidine, 3TC), didanosine (20,30-dideoxyi-
nosine, ddI), or stavudine (30-deoxy-20,30-didehydrothymidine,
d4T). These drugs exert their antiretroviral effects by incorporation
into viral DNA, and, after phosphorylation, causing inhibition of the
reverse transcriptase enzyme (RT) (Olivero et al., 2002). AZT, the
ﬁrst compound that was approved by the FDA, was for a long time
used as a monotherapy. Since 1994, AZT has been recommended
for prevention of vertical transmission of HIV-1 (Connor et al.,
1994). However, recent studies have demonstrated that thease inhibitor; HAART, highly
idine; ddI, 20 ,30-dideoxyino-
y-20 ,30-didehydrothymidine;
TK, thymidine kinase gene;
, low of heterozigosity; MH,
nd ﬂr3; BH, heterozygous for
er OzA license. combination of AZT with other available compounds leads to a
more sustained viral suppression (Meng et al., 2000). The use of
AZT + ddI, AZT + 3TC or d4T + 3TC combinations have been demon-
strated to show a sustained reduction in plasma viremia, with an
increased CD4 count, thus showing clear clinical beneﬁts (Peter
and Gambertoglio, 1998). Moreover, AZT in combination with an-
other NRTI in cesarean proceedings showed an approximately 2%
reduction in the viral transmission rate (Panburana et al., 2004).
However, the combination of two NRTIs can amplify the geno-
toxic effects observed due to increased risk of damage to DNA
caused by these drugs (Carter et al., 2007; Von Tungeln et al.,
2007). Several tests performed with these chemicals individually,
in vitro and in vivo, have demonstrated extensive damage to
nuclear and mitochondrial DNA that may be involved in mutagenic
and carcinogenic effects (Carter et al., 2007; Olivero et al., 2002;
Physicians’ Desk Reference, 2000; Schilling et al., 1995).
The toxic manifestations of AZT incorporation into cellular DNA
have long been investigated and include the induction of
micronuclei, sister chromatid exchange, chromosomal aberrations,
mitochondrial damage, reduction in telomere length and increased
intracellular production of reactive oxygen species (Bialkowska
et al., 2000; Bishop et al., 2004; Desai et al., 2009; Gonzalez Cid
and Larripa, 1994; IARC 2000; Ji et al., 2005; Von Tungeln et al.
2004; Wu et al., 2011).
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entiation of vaginal epithelium and causes vaginal tumors in
experimental animals (Ayers et al., 1996; Olivero et al., 1994). Fur-
thermore, rats trans-placentally exposed to AZT show an increased
incidence of tumors in several organs (Diwan et al., 1999; Olivero
et al., 1997; NTP, 2006; Walker et al., 2007). In other studies, trans-
placental or neonatal administration of NRTIs alone or in combina-
tion resulted in increased mutation frequencies in the TK and HPRT
genes in mice (Carter et al., 2007; Meng et al., 2000; Mittelstaedt
et al., 2004; Torres et al., 2007; Von Tungeln et al., 2002, 2004,
2007).
Here we employed the standard version of the wing SMART in
Drosophila melanogaster (Andrade et al., 2003; Graf et al., 1984)
to obtain a more detailed knowledge of the genotoxic proﬁles of
NRTI combinations of AZT with ddI, 3TC or d4T. The mutational
and recombinational potential as well as the total genotoxicity as
a function of exposure concentration was determined for all
combinations.2. Material and methods
2.1. Chemicals
AZT (30-azido-30-deoxythymidine; CASNR 30516-87-1), ddI (20 ,30-dideoxyino-
sine; CASNR 69655–05-6), 3TC ([] 20-deoxy-30-thiacytidine; CASNR 134678-17-
4) and d4T (30-deoxy-20 ,30-didehydrothymidine; CASNR 3056-17-5) were obtained
from Indústria Química de Goiás (IQUEGO, Goiânia, GO, Brazil), Hospital de Doenças
Tropicais (HDT, Goiânia, GO, Brazil) and from the Fundação para o Remédio Popular
(FURP, Guarulhos, SP, Brazil). All solutions and dilutions of the compounds were
prepared immediately prior to use. AZT, 3TC, d4T, AZT + 3TC and AZT + d4T were
dissolved in distilled water, while ddI and AZT + ddI were dissolved in 5% tween-
80 containing 5% ethanol. Both solvents were used as negative controls.2.2. Somatic mutation and recombination test (SMART)
The SMART protocol is based on the identiﬁcation of wing hairs with mutant
phenotypes that represent the phenotypic manifestation of the occurrence of
DNA damage, including point and chromosomal mutations, as well as mitotic
recombination. Such alterations are primordially induced in the larval-stage cells
of imaginal discs that mitotically divide to give origin to the adult ﬂy’s wings
(Andrade et al., 2003; Graf et al., 1984). This occurs due to induction of loss of
heterozygosity (LOH) of two marked genes involved in the metabolic pathways of
wing hairs (mwh and ﬂr3) (Andrade et al., 2004; Graf et al., 1984).2.3. Standard crossing (ST)
The ST crossing (ﬂr3 virgin females x mwh males) originates larvae with two
genotypic constitutions: (i) mwh +/+ ﬂr3 (MH) – trans-heterozygous for the reces-
sive markers mwh and ﬂr3; and (ii) mwh +/TM3, BdS (BH) – heterozygous for bal-
ancer chromosome TM3 (Graf and van Schaik, 1992).
The induction of LOH in the MH ﬂies produces two mutant clones: (i) single
spots, either mwh or ﬂr3, resulting from point or chromosomal mutations as well
as mitotic recombination, and (ii) twin spots, consisting of both mwh and ﬂr3 sub-
clones, which originate exclusively from mitotic recombination (Graf et al., 1984).
In the BH genotype, mwh spots reﬂect predominantly somatic point mutation
and chromosome mutation, since mitotic recombination involving the balancer
chromosome and its structurally normal homologue is a lethal event (Vogel et al.,
1999).2.4. Treatments
Eggs from both ST cross progenies were collected and placed for 8 h in culture
bottles containing a solid agar base (5% w/v agar in water) covered with a 5 mm
layer of live baker’s yeast supplemented with sucrose. After 72 ± 4 h, third-instar
larvae were collected by ﬂotation in running water and placed in bottles containing
0.9 g of Drosophila Instant Medium (Carolina Biological Supply, Burlington, NC),
rehydrated with 3 mL of the test solutions at different concentrations. The larvae
were fed on this medium for the rest of their development (48 h). After eclosion,
adult ﬂies were collected from the treatment vials and stored in 70% ethanol. Sub-
sequently, the wings of the two progeny ﬂy groups were mounted on slides and
scored under 400Xmagniﬁcation for the presence of cell clones showing malformed
wing hairs. All experiments were carried out at 25 C and 65% relative humidity
(Andrade et al., 2003).2.5. Statistical analysis
The data were evaluated according to the multiple decision procedure proposed
by Frei andWürgler (1988, 1995) resulting in four possible diagnoses: positive, neg-
ative, inconclusive, or weakly positive. The relative frequencies of each group of
spots were compared with the respective negative control using the conditional
binomial test of Kastenbaum and Bowman (1970). Since small single spots and total
spots have a comparatively high spontaneous frequency, m is ﬁxed at a value of 2
(testing for a doubling of the spontaneous frequency). For the large single spots
and the twin spots, which have a low spontaneous frequency,m = 5 is used. Because
false-positive results might occur if the data are overdispersed, all inconclusive, po-
sitive and weak-positive results were analyzed with the non-parametric U-test of
Mann, Whitney, andWilcoxon. The U-test takes into account the rank values in con-
trols and treatments and considers over-dispersion in a non-normal distribution
(Frei and Würgler, 1995). The recombinagenic action of the drugs was calculated
by comparing the standard frequency of clones per 105 cells obtained from MH
and BH genotypes (Frei et al., 1992). For an unbiased comparison of this frequency,
only mwh clones in mwh single spots and twin spots were used (Frei and Würgler,
1996).
The combination indexes of drugs (CI), deﬁned by the Loewe additivity principle
(1957), were calculated according to Ramakrishnan and Jusko (2001), using the re-
sults of the genotoxicity data. CI values were calculated from frequency of clone
induction per 105 cells, control corrected, as CI = [(fA/fAB) + (fB/fAB)], where fA, fB
and fAB are the frequencies induced by drugs alone (A or B) and in combination (AB).3. Results
In the series of experiments performed with the wing SMART
bioassay, the genotoxic potentials of AZT, ddI, 3TC, d4T as well as
AZT + ddI, AZT + d4T, AZT + 3TC combinations were assayed in
two chronic and independent experimental procedures. As the data
from each individual experiment were not heterogeneous (P
clearly < 0.05 in the Kruskall-Wallis test), all data were pooled for
statistical testing. In all combinations, AZT concentrations were
the same and NRTI proportions were 2:1 (AZT + 3TC), 5:3 (AZT +
ddI) and 1:1 (AZT + d4T), according to literature (HIV Trialists’
Collaborative Group, 1999; Kumar et al., 2006; De Clercq, 2009).
Drugs were also tested individually, at the same concentrations
as those used in the combinations, in order to compare the effects
of each drug individually with their effects in combination.3.1. Toxic effects
To determine the concentrations used in genotoxicity analysis,
survival curves were established for each drug alone and in combi-
nation as shown in Fig. 1 and Fig. 2 respectively.
AZT alone was the only treatment that showed survival rates
higher than 95% at all concentrations. This drug showed no toxic
effects even at the highest concentration tested (50 mg.mL1).
3TC showed toxic effects at concentrations P6.25 mg.mL1, dem-
onstrating less than 30% survival. Among the tested NRTIs, 3TC
had the highest toxicity, d4T was toxic at concentrations
P12.5 mg.mL1 and ddI showed toxicity only at the highest con-
centration tested (30 mg.mL1). The combination AZT + 3TC
showed less than 30% ﬂy survival only when the concentration
was 50 + 25 mg.mL1. Interestingly, 3TC showed a large reduction
in its toxic potential when associated with AZT, and showed more
than 65% survival in ﬂies until the concentration reached
12.5 mg.mL1. AZT + ddI resulted in less than 30% survival ﬂies
only at a concentration of 50 + 30 mg.mL1. Thus, ddI showed a
reduction in its toxic potential, and did not maintain its pattern
of toxicity even in the presence of AZT (see Fig. 2). On the other
hand, AZT + d4T showed toxicity at the two highest concentrations
tested (12.5 + 12.5 and 25 + 25 mg.mL1). As with ddI, d4T main-
tained its pattern of toxicity even in the presence of AZT. Only
those concentrations which effectively had a survival rate exceed-
ing 30% were used in the assessment of genotoxicity.
Fig. 1. Relative percentage of survival of ﬂies detected after metamorphosis of third-stage larvae treated with different concentrations of AZT, 3TC, d4T and ddI.
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The analysis of MH individuals showed mutational and recom-
binational events that are expressed phenotypically as single
(small or large) and twin spots. In the assays performed with indi-
vidual drugs (Table 1) we observed that AZT and 3TC were able to
increase the total spot frequencies and showed positive statisticalcorrelation at all tested concentrations. For ddI and d4T, however,
the lowest concentrations showed inconclusive results. Except for
AZT, all NRTI treatments showed dose-dependent effects. Consid-
ering mwh clones from mwh single spots and from twin spots
(n), was possible to calculate the mean mwh clone size class (î).
This ﬁgure represents the clone size class in which the majority
of clones induced by a speciﬁc treatment is located (de Andrade
Fig. 2. Relative percentage of survival of ﬂies detected after metamorphosis of third-stage larvae treated with different concentrations of combined AZT + 3TC, AZT + d4T and
AZT + ddI.
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(î) were around 2–3 for almost all treatments, indicating that the
small single spots were the major responsible for the increase in
total spot frequencies observed after the AZT and ddI treatments.
These results indicate that the NRTI single and combination treat-
ments acted at the end of mitotic cell cycle. 3TC showed the high-
est relative frequency rates among the NRTIs evaluated in this
study. While AZT, ddI and d4T had induced relative frequency rates
ranging from 0.80 to 2.80 for total spot induction, 3TC relative fre-
quencies ranged from 10.67 to 21.03, and exhibited a dose–re-
sponse relationship.
Among the three combinations evaluated (Table 2) all NRTI
combination assays showed positive and dose–response relation-
ships. AZT + 3TC resulted in the highest frequencies for all types
of spots. This combination showed a positive correlation withsmall single, large single and twin spots, at all concentrations,
when compared with their negative controls respectively.
On the other hand, the AZT + d4T combination showed lower
mutant spot rates than the AZT + ddI and AZT + 3TC combinations.
While AZT + ddI showed a total frequency of spots ranging from
3.50 to 12.67, the relative frequencies for AZT + 3TC ranged from
5.0 to 16.13, and for AZT + d4T was no more than 1.05 to 1.88.
AZT + d4T did not induce statistically signiﬁcant increases in the
frequencies of small single spots (in all treated series), but in-
creased the induction of large single spots and twin spots, when
compared with their negative controls respectively.
The comparison between AZT alone and in combinations
showed that only AZT + d4T combination do not induced statisti-
cally increasing in frequencies of almost all spots in relation of
AZT alone (Table 2).
Table 1
Evaluation of the mutagenic and/or recombinagenic effects of the NRTIs in somatic cells larvae proceeding from standard cross.
Genotype and compounds N. of ﬂies Spots per ﬂy (no. of spots) statistical diagnosisa Total mwh clonesc Mean mwh clone size classg Frequency of clone induction
per 105 cellsd (n/NC)e
Small single spots (1–2 cells)b Large single spots (>2 cells)b Twin spots Total spots
(mg. mL1) (N) m = 2 m = 5 m = 5 m = 2 (n) (î) Observed Control corrected
AZT
mwh/ﬂr3
Negative control 40 0.40 (16) 0.13 (05) 0.05 (02) 0.58 (23) 22 2.23 1.13
1.5625 40 1.28 (51)+ 0.53 (21) + 0.25 (10) + 2.05 (82) + 81 2.36 4.15 3.02
3.125 40 0.95 (38) + 0.50 (20) + 0.28 (11) + 1.73 (69) + 67 2.61 3.43 2.31
6.25 40 1.23 (49) + 0.43 (17) + 0.25 (10) + 1.90 (76) + 76 2.38 3.89 2.77
12.5 40 0.43 (17)  0.35 (14) + 0.30 (12) + 1.08 (43) + 43 3.07 2.20 1.08
25 40 0.90 (36) + 0.40 (16) + 0.15 (06)  1.45 (58) + 54 2.43 2.77 1.64
mwh/TM3
Negative control 40 0.28 (11) 0.08 (03) f 0.35 (14) 14 1.71 0.72
1.5625 40 0.25 (10)  0.05 (02)  0.30 (12)  12 1.75 0.61 0.10
3.125 40 0.30 (12)  0.18 (07)  0.48 (19)  19 2.00 0.97 0.26
6.25 40 0.38 (15)  0.05 (02)  0.43 (17)  17 1.59 0.87 0.15
12.5 40 0.30 (12)  0.05 (02)  0.35 (14)  14 1.57 0.72 0.00
25 40 0.35 (14)  0.05 (02)  0.40 (16)  16 1.69 0.82 0.10
ddI
mwh/ﬂr3
Negative control 40 0.45 (18) 0.08 (03) 0.00 (00) 0.53 (21) 21 1.71 1.08
0.9375 40 0.60 (24)  0.20 (08)  0.00 (00) 0.80 (32)  32 1.91 1.64 0.56
1.875 40 0.73 (29)  0.20 (08)  0.08 (03)  1.00 (40) + 40 2.05 2.05 0.97
3.75 40 0.68 (27)  0.40 (16) + 0.13 (05) + 1.20 (48) + 48 2.63 2.46 1.38
7.5 40 1.20 (48) + 0.28 (11) + 0.18 (07) + 1.65 (66) + 66 2.08 3.38 2.31
15 40 1.78 (71) + 0.90 (36) + 0.13 (05) + 2.80 (112) + 112 2.25 5.74 4.66
mwh/TM3
Negative control 40 0.38 (15) 0.03 (01) f 0.40 (16) 16 1.69 0.82
0.9375 40 0.20 (08)  0.05 (02)  0.25 (10)  10 1.70 0.51 0.31
1.875 40 0.13 (05)  0.03 (01)  0.15 (06)  06 2.00 0.31 0.51
3.75 40 0.23 (09)  0.08 (03)  0.30 (12)  12 1.92 0.61 0.20
7.5 40 0.28 (11)  0.03 (01)  0.30 (12)  12 1.83 0.61 0.20
15 37 0.24 (09)  0.08 (03)  0.32 (12)  12 1.92 0.66 0.16
3TC
mwh/ﬂr3
Negative control 30 0.57 (17) 0.13 (04) 0.03 (01) 0.73 (22) 22 2.45 1.50
0.78125 30 5.23 (157) + 3.77 (113) + 1.67 (50) + 10.67 (320) + 320 2.66 21.86 20.36
1.5625 30 7.43 (223) + 7.17 (215) + 2.40 (72) + 17.00 (510) + 498 2.90 34.02 32.51
3.125 30 7.83 (235) + 10.17 (305) + 3.03 (91) + 21.03 (631) + 611 3.07 41.73 40.23
mwh/TM3
Negative control 30 0.53 (16) 0.03 (01) f 0.57 (17) 17 1.24 1.16
0.78125 30 2.30 (69) + 0.57(17) + 2.87 (86) + 86 1.71 5.87 4.71
1.5625 30 2.53 (76) + 0.57 (17) + 3.10 (93) + 93 1.90 6.35 5.19
3.125 30 3.17 (95) + 0.90 (27) + 4.07 (122) + 122 1.87 8.33 7.17
d4T
mwh/ﬂr3
Negative control 30 0.67 (20) 0.07 (02) 0.03 (01) 0.77 (23) 23 1.70 1.57
1.5625 30 0.93 (28)  0.10 (03)  0.03 (01)  1.07 (32)  32 1.88 2.19 0.61
3.125 30 0.90 (27)  0.33 (10) + 0.20 (06)  1.43 (43) + 43 2.70 2.94 1.37
6.25 30 0.60 (18)  0.87 (26) + 0.33 (10) + 1.80 (54) + 53 4.19 3.62 2.05
mwh/TM3
Negative control 30 0.50 (15) 0.00 (00) f 0.50 (15) 15 1.20 1.02
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To establish the percentage of mutation and recombination in-
duced by NRTIs, we compared the results obtained from MH and
BH genotypes. The MH individuals can express phenotypes related
to mutational and recombinational damage, whereas BH individu-
als can express only mutational events, because the TM3 chromo-
some has multiple inversions that make the products of
recombination unviable. Thus, differences between the spot fre-
quencies induced in MH and BH ﬂies allow calculation of the fre-
quency of mutational and recombinational events.
Among the individual drugs, ddI was completely recombinagen-
ic (<100%) while d4T induced the lowest recombination rates
(50.36% and 73.17%) (Table 3). AZT results ranged from 88.74% to
100% for induced recombinagenic events, while for 3TC the fre-
quency ranged from 76.87% to 84.04%. Neither showed a dose-
dependent relationship. Since the lower concentrations of ddI
and d4T alone did not signiﬁcantly increase the frequencies of in-
duced spots in MH individuals, it was not possible to calculate the
recombination and mutation percentages.
No drug combinations showed a dose-dependent relationship
for recombination or mutation frequencies. The AZT + ddI and
AZT + 3TC combinations induced mitotic recombination ranging
between 86.38% and 98.36%, maintaining the same behavior as
AZT alone. On the other hand, AZT + d4T showed a large discrep-
ancy between recombination and mutation percentages.3.4. Analysis of combination index (CI)
CI values were calculated using the data from control-corrected
frequencies described in Table 1. These results are listed in Table 3,
and represent the comparison between single drugs and the corre-
sponding combinations of two drugs. This index detects the inter-
active effects of the drugs when used in combination (Loewe,
1957), and is calculated according Ramakrishnan and Jusko
(2001), and deﬁned by the Loewe additivity principle (1957) as
the sum of the relative frequencies of clone induction per 105 cells:
CI = [(fA/fAB)+(fB/fAB)]. When the CI is 1, the interaction is additive,
while CI values >1 and <1 represent, respectively, antagonistic
and synergistic interactions.
In our results, all combinations showed CI values that differed
from 1. AZT + ddI was the only combination that showed a CI value
<1, since the observed frequency in combination was higher than
all of the single drug values. In summary, AZT demonstrated a syn-
ergistic effect in combination with ddI and an antagonistic effect in
AZT + 3TC and AZT + d4T combinations. Moreover, we can observe
that the frequencies induced by 3TC alone were much higher than
the frequencies induced when in combination with AZT.4. Discussion
The present study investigated the mutagenic and recombina-
genic effects of NRTI cocktails. We compared the frequencies for
combinations and single drugs in terms of total number of mutant
spots in order to investigate the interaction between AZT and three
other NRTIs with respect to the inﬂuences of these interactions on
DNA-damaging events. The effects demonstrated here after indi-
vidual drug treatments conﬁrm earlier results obtained from the
SMART wing test, as performed by our laboratory and reported in
previous publications (Franchi et al., 2009; Guimarães et al.,
2008). The necessity of combining two or more NRTIs appeared
due to the development of several mutations in the HIV genome
that caused viral resistance and failure of many treatments con-
ducted with single drugs (Bossi et al., 1998; Duan et al., 2001;
Ehtheshami et al., 2008; Parikh et al., 2006; Re et al., 2003; Turner
Table 2
Evaluation of the mutagenic and/or recombinagenic effects of the NRTIs combination in somatic cells larvae proceeding from standard cross.
Genotype and
compounds
N. of ﬂies Spots per ﬂy (n of spots) statistical diagnosisa Total mwh clonesc Mean clone size classg Frequency of clone induction per 105 cellsd (n/
NC)e
Small single spots Large single spots Twin Spots Total spots
(1–2 cells)b (> 2 cells)b m = 5 m = 5 m = 2
(mg. mL1) (N) m = 2 h i h i h i h i (n) (î) Observed Control corrected
AZT ddI
mwh/ﬂr3
Negative control 38 0.42 (16) 0.11 (4) 0.03 (1) 0.55 (21) 21 1.81 1.13
1.5625 0.9375 36 2.19 (79) + + 0.86 (31) + + 0.44 (16) +  3.50 (126) + + 126 2.31 7.17 6.04
3.125 1.875 39 3.23 (126) + + 1.44 (56) + + 0.31(12) +  4.97 (194) + + 193 2.25 10.14 9.01
6.25 3.75 39 2.38 (93) + + 2.21 (86) + + 1.15 (45) + + 5.74 (224) + + 222 2.92 11.66 10.53
12.5 7.5 38 3.95 (150) + + 3.47 (132) + + 1.61 (61) + + 9.03 (343) + + 340 2.90 18.33 17.20
25 15 30 5.30 (159) + + 5.47 (164) + + 1.90 (57) + + 12.67 (380) + + 371 2.99 25.34 24.21
mwh/TM3
Negative control 37 0.32 (12) 0.03(1) f 0.35 (13) 12 1.25 0.66
1.5625 0.9375 37 0.32 (12)   0.05 (2)   0.38 (14)   14 1.64 0.78 0.11
3.125 1.875 39 0.56 (22) +  0.05 (2)   0.62 (24)   24 1.71 1.26 0.60
6.25 3.75 40 0.85 (34) + + 0.10 (4) +  1.03 (41) + + 38 1.71 1.95 1.28
12.5 7.5 40 1.00 (40) + + 0.18 (7) +  1.18 (47) + + 47 1.72 2.41 1.74
25 15 40 0.65 (26) + + 0.35 (14) + + 1.00 (40) + + 40 2.30 2.05 1.38
AZT 3TC
mwh/ﬂr3
Negative control 40 0.45 (18) 0.05(2) 0.00(0) 0.50(20) 20 1.60 1.02
1.5625 0.78125 40 2.53 (101) + + 1.53 (61) + + 0.95(38) + + 5.00 (200) + + 198 2.76 10.14 9.12
3.125 1.5625 40 2.90 (116) + + 1.88 (75) + + 0.90(36) + + 5.68 (227) + + 225 2.62 11.53 10.50
6.25 3.125 40 6.40 (256) + + 5.45 (218) + + 2.08(83) + + 13.93 (557) + + 549 2.81 28.13 27.10
12.5 6.25 40 5.85 (234) + + 7.00 (280) + + 2.53(101) + + 15.38 (615) + + 598 2.99 30.64 29.61
25 12.5 40 7.85 (314) + + 5.88 (235) + + 2.40(96) + + 16.13 (645) + + 733 2.83 37.55 36.53
mwh/TM3
Negative control 40 0.38(15) 0.05(2) f 0.43(17) 17 1.47 0.87
1.5625 0.78125 40 0.35 (14)   0.15 (6)   0.50 (20)   20 2.05 1.02 0.15
3.125 1.5625 40 1.00 (40) + + 0.15 (6)   1.15 (46) + + 45 1.49 2.31 1.43
6.25 3.125 40 1.43 (57) + + 0.20 (8)  + 1.63 (65) + + 65 1.69 3.33 2.46
12.5 6.25 37 2.38 (88) + + 0.54 (20) + + 2.92 (108) + + 107 1.94 5.93 5.06
25 12.5 40 1.45 (58) + + 0.43 (17) + + 1.88 (75) + + 74 2.03 3.79 2.92
AZT d4T
mwh/ﬂr3
Negative control 40 0.48 (19) 0.10(4) 0.03 (1) 0.60(24) 24 1.92 1.23
1.5625 1.5625 40 0.50 (20)  + 0.43 (17) +  0.13 (5)   1.05 (42) + + 40 3.03 2.05 0.82
3.125 3.125 40 0.60 (24)  + 0.43 (17) +  0.25 (10) +  1.28 (51) +  50 3.24 2.56 1.33
6.25 6.25 40 0.73 (29)  + 0.83 (33) + + 0.33 (13) +  1.88 (75) +  70 4.01 3.59 3.36
mwh/TM3
Negative control 40 0.33 (13) 0.13 (5) f 0.45(18) 17 1.76 0.87
1.5625 1.5625 40 0.40 (16)   0.03 (1)   0.43 (17)   17 1.47 0.87 0.00
3.125 3.125 40 0.53 (21)   0.15 (6)   0.68 (27)   27 2.07 1.38 0.51
6.25 6.25 40 0.40 (16)   0.15 (6)   0.55 (22)   21 2.38 1.08 0.20
a Statistical diagnosis according to Frei and Würgler (1988): +, positive; , negative; i, inconclusive. m, factor of multiplication for evaluation of results signiﬁcantly negativies. Levels of signiﬁcance P < 0.05.
b Including rare single spots ﬂr3.
c Considering clones mwh for single spots mwh and for twin spots.
d Calculated accordance with Frei et al. (1992).
e C = 48.800, i.e., approach number of cells examined for individual.
f Just single spots mwh be can observed in heterozygous individual mwh/TM3, since balancer chromosome TM3 do not contain the mutant gene ﬂr3.
g Considering mwh clones from mwh single and twin spots.
h Statistical diagnoses for comparison with negative control.
i Statistical diagnoses for comparison with AZT alone.
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Table 3
Percentage of mutation and recombination to clone induction frequencies per 105 cells per cell division in ﬂies treated with different concentrations.
Compound (mg.mL1) R M Compounds (mg.mL1) R M CI
AZT
1.5625 96.69 3.31
3.125 88.74 11.26
6.25 94.58 5.42
12.5 100.00 0.00
25 93.90 6.10
ddI AZT ddI
0.9375 a a 1.5625 0.9375 98.18 1.82 0.59
1.875 152.58 52.58 3.125 1.875 93.34 6.66 0.36
3.75 114.49 14.49 6.25 3.75 87.84 12.16 0.39
7.5 108.66 8.66 12.5 7.5 89.88 10.12 0.20
15 103.43 3.43 25 15 94.30 5.70 0.26
d4T AZT d4T
1.5625 a a 1.5625 1.5625 100.00 0.00 4.43
3.125 50.36 49.64 3.125 3.125 61.65 38.35 2.77
6.25 73.17 26.83 6.25 6.25 91.53 8.47 1.43
3TC AZT 3TC
0.78125 76.87 23.13 1.5625 0.78125 98.36 1.64 2.56
1.5625 84.04 15.96 3.125 1.5625 86.38 13.62 3.32
3.125 82.18 17.82 6.25 3.125 90.92 9.08 1.59
12.5 6.25 82.91 17.09 b
25 12.5 92.01 7.99 b
a There was no increase in the frequency of induction spots in these concentrations applied.
b It was not possible to calculate the CI, because no individual was born in these concentrations of 3TC alone. R: percentage of recombination; M: percentage of mutation;
CI: combination index. R and M were calculated according to Frei and Würgler (1996): R = 1  [(n/NC in mwh/TM3 ﬂies)/(n/NC in mwh/ﬂr3 ﬂies)]  100; M = 100  R. CI was
calculated according Ramakrishnan and Jusko (2001) and deﬁned by Loewe additivity principle (1957): CI = [(fA/fAB) + (fB/fAB)], where f is the frequency of clone induction per
105 cells. Control corrected frequencies were used for these calculations.
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or more types of nucleoside analogues into the cells may result in
disturbances in the natural deoxynucleotide pool, and these imbal-
ances may contribute to the triggering of genomic instability and
raise the risk of repairable or permanent injuries for the nuclear
and mitochondrial DNA (Bebenek et al., 1992; Kunz et al., 1994;
Mathews, 2006; Morris et al., 2009; Olivero et al. 2006). Even in
the 1980s, some studies demonstrated that the presence of AZT
in the cytoplasm altered the pool of most natural deoxynucleoside
triphosphates (dNTPs). In a trial using HL-60, H-9 and K-562 cells,
incubated with 200 lM AZT, there were substantial ﬂuctuations in
the pool of dNTPs. The deoxythymidine triphosphate (dTTP) and
deoxyguanosine triphosphate (dGTP) pools in all three cell types
were reduced while the pool of deoxycytidine triphosphate (dCTP)
was increased. The deoxyadenosine triphosphate (dATP) pool did
not suffer interference in the presence of AZT (Frick et al., 1988;
Frick and Nelson, 1989).
In another report, Johnson et al. (2001) investigated the causes
of mitochondrial toxicity induced by NRTIs, determining whether
mitochondrial genome replication was delayed in the presence of
each analog, based on discrimination rates from NRTI incorpora-
tion by polymerases versus exonuclease removal rates. It was con-
cluded that the AZT toxicity was due to more effective exonuclease
AZTTP excision rather than the rate of its incorporation. Con-
versely, the high toxicity of ddI (metabolized to ddA) was due to
the combination of high levels of incorporation into the mtDNA
by polymerases as well as its inefﬁcient removal by exonucleases.
Correlating these analyses with our results in somatic cells of
Drosophila melanogaster, we suggest that the presence of AZT and
ddI in these cells increased the supply of AZTTP and ddATP, which
competed with endogenous nucleosides (dTTP and dATP) for poly-
merases, inducing higher rates of DNA damage in the somatic cells
of the wings, thereby resulting in synergy. We believe that the
stronger contribution of ddI to this synergy was due the higher
resistance of ddATP caused by exonuclease excision and the lower
AZT toxicity.Moreover, the kinetic effects of AZT on natural deoxythymidine
(dT) and deoxycytidine (dC) phosphorylation may cause an imbal-
ance in the production of mitochondrial deoxythymidine mono-
phosphate (dTMP). The mitochondrial thymidine kinase (TK2)
enzyme is responsible for both dT and dC phosphorylation but
has a higher afﬁnity for the dT nucleoside. In the presence of
AZT, Wang et al. (2011) demonstrated a reduction in dT phosphor-
ylation (by 50%), decreasing the dTTP pool, and an increase in the
dCTP pool (of 30%). As AZT and dT are base analogues, the AZT
and dT competition for the TK2 enzyme could explain these data,
that are in agreement with those reported by Frick et al. (1988). Ta-
ken together, this leads us to conclude that the presence of AZT
greatly increased the intracellular dC pool and increased the 3TC
and dC competition for the deoxycytidine kinase enzyme (dCK),
thereby producing more dCTP rather than 3TCTP, reducing the
DNA damage and consequently reducing the mutant spot frequen-
cies. Furthermore, Johnson et al. (2001) established and deﬁned a
toxicity index for chain terminators as relative rates of incorpora-
tion versus removal and demonstrated that, in mitochondria, the
3TCTP toxicity index was slightly higher than the AZTTP index,
since the removal of 3TC by exonucleases was more difﬁcult in
the presence of both AZT and 3TC nucleosides in the cell.
The analyses of the antagonism shown by the AZT + d4T combi-
nation requires another approach since these two drugs are ana-
logues of the same nucleoside. All three substrates (AZT, d4T and
dT) are phosphorylated in three steps using thymidine kinase, thy-
midylate kinase and nucleoside diphosphate kinase, respectively
(von Kleist et al., 2012). For d4T, the thymidine kinase reaction is
the limiting step while for AZT it is the thymidylate kinase reaction
(De Clercq, 2009; Ho and Hitchcock, 1989; von Kleist et al., 2012).
d4T does not interfere in the ﬁrst step of dT or AZT phosphorilation
since it has a lower afﬁnity for thymidine kinase than do AZT and
dT. However, AZTMP interferes in dTMP phosphorylation because
both have the same afﬁnity for thymidylate kinase. The presence
of high extracellular AZT concentrations increases the AZTMP con-
centration, and this competes with dTMP for thymidylate kinase,
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Moreover, Lavie et al. (1997) demonstrated that AZTMP, but not
dTMP, acts as a thymidylate kinase allosteric inhibitor. AZTMP
can bind simultaneously with high afﬁnity to both ATP and deox-
inucleoside binding sites on the thymidylate kinase enzyme. This
occurs because the AZT 30-azido group (N3) opens the loop P frame
of thymidylate kinase and exposes its ATP binding site, thereby
promoting the attachment of AZTMP to both sites. Thus a high
cytoplasmatic AZTMP concentration blocks the thymidylate kinase
activity. For allosteric reasons this does not happen with dTMP,
which is converted to dTDP and dTTP faster than the AZTMP to
AZTDP and AZTTP (Lavie et al., 1997).
We should also consider a few studies describing the fact that
AZT can be transformed into d4T (Becher et al., 2003; Benech
et al., 2006; Bonora et al., 2004). Benech et al. (2006) reported that
a number of tests performed by this group have found moderate
amounts of d4TTP in cells treated only with AZT. Structurally,
AZT has a N3 radical instead of a hydroxyl group on the 30carbon
of the thymidine deoxyribose, while d4T has hydrogen (De Clercq,
2009). The AZT transformation to d4TTP (Benech et al., 2006), as
well as the ability of cells to synthesize d4TTP is concomitant with
normal dTTP levels (Ho and Hitchcock, 1989), and the interference
of AZTMP in the dTTP pool (von Kleist et al., 2012) could explain
the antagonism of AZT + d4T shown in our experiments and other
tests.
The excess of a dNTP can trigger a series of events in the cell cy-
cle such as non-Watson–Crick base pair formation and defective
replicative DNA chain elongation, before revision and correction
by 30exonucleases, thus resulting in events ranging from point
mutations to chromosomal aberrations (Mathews, 2006). In mur-
ine embryonic stem cell (mES) cultures treated with 100 lM AZT,
Campos et al. (2011) demonstrated that there was a great increase
in the aneuploid cell proportion, with a preponderance of chromo-
some loss, accompanied by an increase in micronucleus formation
in mES cell colonies. These data suggest that AZT exerts genotoxic
effects and increases chromosomal instability at early stages of
embryonic development.
Defects in mitotic checkpoints have been implicated as one
cause of chromosomal instability in several different studies. The
consequence of this instability is LOH of tumor suppressor genes
because it accelerates the erroneous segregation of the wild type
allele during chromosome transport (Borojerdi et al., 2009). There
is evidence for a potential mechanism whereby the chromosomal
instability can promote tumorigenesis, as a correlation between
aneuploidy and LOH of tumor suppressor genes (Baker et al., 2009).
LOH is one of the genetic alterations most frequently observed
in sporadic tumors and is also presumed to be an obligatory step
in the emergence of various hereditary cancer types involving tu-
mor suppressor genes (Stark and Jasin, 2003). Chromosomal dou-
ble-chain breaks are extremely potent inducers of homologous
recombination in mammalian cells, raising the question regarding
to what extent they can produce lesions with LOH by allelic recom-
bination. In addition to mitotic recombination, gene conversions,
deletions, translocations, gene ampliﬁcations and unequal cross-
ing-over are also related to development of certain types of tumors
(Bishop and Schiestl, 2001). All of these potential risks highlight
the importance of deﬁning the mutagenic and recombinagenic pro-
ﬁles of these drugs in the development of antiretroviral treatment
protocols. Using the SMART bioassay we analyzed the prevalence
of NRTI-induced mutagenic and recombinagenic effects and ques-
tioned whether these effects change with the combination treat-
ments. The AZT + ddI and AZT + 3TC combinations demonstrated
similar behavior, with a predominance of induced mitotic recombi-
nation events (86.38–98.36%), without a dose-dependent relation-
ship, showing the same characteristics as treatment with
individual drugs. On the other hand, the large variation inAZT + d4T recombinagenic rates reﬂects the high degree of insta-
bility caused by the presence of two thymidine analogues in the
intracellular environment.
There is a similarity between the desoxirribonucleoside kinase
(Dm-dNK) enzyme of D. melanogaster and mammalian enzymes
(Johansson et al., 1999). Although pyrimidine nucleosides are the
preferred substrates for Dm-dNK, it catalyzes the phosphorylation
of all natural pyrimidine and purine deoxyribonucleosides and also
efﬁciently phosphorylates several antiviral and anticancer nucleo-
sides (Munch-Petersen et al., 1998).
The similarity of the Dm-DNK enzyme to mammalian cell en-
zymes (Johansson et al., 1999) and the safe phenotypic analysis
of the induced genetic lesions highlight the wing SMART test as
an important tool for the detection of mutagenic and recombina-
genic effects by a range of substances, including antiretrovirals
drugs. The presence of marker genes for wing hair phenotypes, in
mwh and ﬂr3 strains, allowing the detection of mutations and
recombination induction and also the relative proportions of each
these events, is another great advantage of the SMART bioassay.
The use of NRTIs in HAART has shown excellent results in the
reduction of virulence and improvement of AIDS patients’ lives,
reducing HIV vertical transmission rates. Therefore, its use must
be maintained in chronic treatment protocols (De Clercq, 2009;
Jin et al., 2011; Warszawski et al., 2008). In addition to the clinical
beneﬁts obtained with the combination of two or more NRTIs, the
use in HAART also emphasizes the maximum effects of drugs at
lower doses, to reduce the ﬁnancial costs of treatment, especially
in underdeveloped countries, where great parts of population do
not have access to emerging modern medicines (De Clercq, 2009;
Makinson et al., 2008).
The analysis of cost-beneﬁts in the use of HAART protocols may
depend on a range of factors, including the constant screening of
genomic alterations induced by single and combined drugs in or-
der to minimize secondary effects and improve treatment
efﬁciency.
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